Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) agreed to acquire the U.S. rights to Eisai Co Ltd’s (OTC: ESALY) (OTC: ESALF) Fycompa (perampanel) CIII and an exclusive option period to review, eval...
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) agreed to acquire the U.S. rights to Eisai Co Ltd’s (OTC: ESALY) (OTC: ESALF) Fycompa (perampanel) CIII and an exclusive option period to review, eval...